An Irish biotechnology company developing drugs to tackle a heart disease that causes sudden death in young athletes has raised $20m (€14.5m) Series A financing for clinical drug trials.

Drug development firm Opsona Therapeutics has raised €33m to fund test work on a product it is developing to help kidney transplant patients amongst others.